Cencora (COR) Stock Forecast & Price Target

$220.80

+1.30 (+0.59%)

(As of 10/8/2024 ET)

Cencora - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 10 Analyst Ratings

Sell
0

Hold
3

Buy
7

Based on 10 Wall Street analysts who have issued ratings for Cencora in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 10 analysts, 3 have given a hold rating, and 7 have given a buy rating for COR.

Consensus Price Target

$259.44
17.50% Upside

According to the 10 analysts' twelve-month price targets for Cencora, the average price target is $259.44. The highest price target for COR is $287.00, while the lowest price target for COR is $224.00. The average price target represents a forecasted upside of 17.50% from the current price of $220.80.

Get the Latest News and Ratings for COR and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Cencora and its competitors.

COR Analyst Ratings Over Time

Type	Current Forecast 10/9/23 to 10/8/24	1 Month Ago 9/9/23 to 9/8/24	3 Months Ago 7/11/23 to 7/10/24	1 Year Ago 10/9/22 to 10/9/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	7 Buy rating(s)	6 Buy rating(s)	6 Buy rating(s)	12 Buy rating(s)
Hold	3 Hold rating(s)	2 Hold rating(s)	3 Hold rating(s)	2 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$259.44	$258.13	$236.10	$189.36
Forecasted Upside	17.50% Upside	9.85% Upside	6.15% Upside	1.70% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

[SHOCKING] Crypto Document Leak… (Ad)

The crypto market waits for no one. And my team of experts and I believe that a BIG move is right around the corner. That's why we're offering you instant access to the game-changing book that's transforming average investors into massive crypto successes.

Download your digital copy now

COR Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

COR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Cencora Stock vs. The Competition

Type	Cencora	Medical Companies	S&P 500
Consensus Rating Score	2.70	2.78	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Hold
Predicted Upside	17.87% Upside	10,819.51% Upside	7.88% Upside
News Sentiment Rating	Positive News See Recent COR News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
10/8/2024	Evercore ISI 2 of 5 stars		Lower Target	Outperform ➝ Outperform	$270.00 ➝ $250.00	+13.62%
10/7/2024	Leerink Partners 1 of 5 stars		Lower Target	Outperform ➝ Outperform	$277.00 ➝ $275.00	+25.03%
9/18/2024	Bank of America 4 of 5 stars		Reiterated Rating	Buy ➝ Neutral	$275.00 ➝ $245.00	+4.46%
9/6/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$287.00 ➝ $283.00	+19.77%
8/21/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$280.00 ➝ $287.00	+20.03%
8/1/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$236.00 ➝ $249.00	+3.96%
Get the Latest News and Ratings for COR and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Cencora and its competitors with MarketBeat's FREE daily newsletter.
4/30/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$265.00 ➝ $280.00	+16.87%
2/26/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Cherny Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
2/5/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$192.00 ➝ $224.00	-4.63%
1/3/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Overweight	$242.00	+16.04%
8/7/2023	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$205.00 ➝ $215.00	+15.07%
8/3/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$176.00 ➝ $190.00	-1.69%
5/26/2023	888 Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Maintains
5/3/2023	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$174.00 ➝ $182.00	+8.81%
1/31/2023	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy	$184.00 ➝ $190.00	+14.94%
1/12/2023	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy	$170.00 ➝ $190.00	+14.88%
11/22/2022	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$175.00 ➝ $182.00	+13.54%
10/18/2022	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform	$170.00 ➝ $169.00	+16.93%
10/11/2022	Bank Of America (Bofa) Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Buy

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 10:15 PM ET.

Should I Buy Cencora Stock? COR Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, October 3, 2024. Please send any questions or comments about these Cencora pros and cons to contact@marketbeat.com.

Cencora
Bull Case

Here are some ways that investors could benefit from investing in Cencora, Inc.:

Cencora's stock price has been showing positive momentum, trading up on recent days, reaching $228.11 on Friday, which could indicate potential growth.
Major institutional investors like Vanguard Group Inc., Price T Rowe Associates Inc. MD, and JPMorgan Chase & Co. have made significant investments in Cencora, indicating confidence in the company's future prospects.
Cencora has a market capitalization of $45.50 billion, a healthy financial indicator that reflects the company's size and stability in the market.
The company has a moderate buy consensus rating from analysts, with an average price target of $256.67, suggesting positive sentiment towards its future performance.
Cencora's business model of sourcing and distributing pharmaceutical products aligns with the essential healthcare sector, providing a stable and potentially lucrative market opportunity.

Cencora
Bear Case

Investors should be bearish about investing in Cencora, Inc. for these reasons:

Insiders, including major shareholder Walgreens Boots Alliance, Inc., have been selling significant amounts of Cencora stock, which could raise concerns about insider sentiment or future performance.
The company's debt-to-equity ratio of 3.93 may indicate a relatively high level of debt, which could pose risks in case of economic downturns or financial challenges.
While Cencora has received positive ratings from analysts, some have downgraded the stock from "strong-buy" to "buy," which could signal potential concerns about future growth prospects.
The stock has a beta of 0.44, indicating lower volatility compared to the market, which may limit potential returns for more risk-tolerant investors seeking higher growth opportunities.
Recent fluctuations in the stock price, with a 1-year low of $178.21 and a high of $247.66, may suggest volatility and uncertainty in the company's performance, which could deter risk-averse investors.

COR Forecast - Frequently Asked Questions

: According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for Cencora is $259.44, with a high forecast of $287.00 and a low forecast of $224.00.
: 10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cencora in the last year. There are currently 3 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" COR shares.
: According to analysts, Cencora's stock has a predicted upside of 17.50% based on their 12-month stock forecasts.
: Cencora has been rated by research analysts at Bank of America, Evercore ISI, JPMorgan Chase & Co., Leerink Partners, Robert W. Baird, and Wells Fargo & Company in the past 90 days.
: Analysts like Cencora less than other "medical" companies. The consensus rating score for Cencora is 2.70 while the average consensus rating score for "medical" companies is 2.78. Learn more on how COR compares to other companies.